| A comprehensive listing of bioactivation pathways of organic functional groups AS Kalgutkar, I Gardner, RS Obach, CL Shaffer, E Callegari, KR Henne, ... Current drug metabolism 6 (3), 161-225, 2005 | 698 | 2005 |
| Analytical strategies for identifying drug metabolites C Prakash, CL Shaffer, A Nedderman Mass spectrometry reviews 26 (3), 340-369, 2007 | 366 | 2007 |
| Partial agonists of the α3β4* neuronal nicotinic acetylcholine receptor reduce ethanol consumption and seeking in rats S Chatterjee, P Steensland, JA Simms, J Holgate, JW Coe, RS Hurst, ... Neuropsychopharmacology 36 (3), 603-615, 2011 | 118 | 2011 |
| Formation of cyclopropanone during cytochrome P450-catalyzed N-dealkylation of a cyclopropylamine CL Shaffer, S Harriman, YM Koen, RP Hanzlik Journal of the American Chemical Society 124 (28), 8268-8274, 2002 | 96 | 2002 |
| N-Dealkylation of an N-Cyclopropylamine by Horseradish Peroxidase. Fate of the Cyclopropyl Group CL Shaffer, MD Morton, RP Hanzlik Journal of the American Chemical Society 123 (35), 8502-8508, 2001 | 91 | 2001 |
| Discovery of trifluoromethyl glycol carbamates as potent and selective covalent monoacylglycerol lipase (MAGL) inhibitors for treatment of neuroinflammation LA McAllister, CR Butler, S Mente, SV O’Neil, KR Fonseca, JR Piro, ... Journal of medicinal chemistry 61 (7), 3008-3026, 2018 | 73 | 2018 |
| Phosphodiesterase type 5 (PDE5) inhibition improves object recognition memory: indications for central and peripheral mechanisms OAH Reneerkens, K Rutten, S Akkerman, A Blokland, CL Shaffer, ... Neurobiology of learning and memory 97 (4), 370-379, 2012 | 72 | 2012 |
| The ELFIN mission V Angelopoulos, E Tsai, L Bingley, C Shaffer, DL Turner, A Runov, W Li, ... Space science reviews 216, 1-45, 2020 | 70 | 2020 |
| Glycine transporter inhibition reverses ketamine-induced working memory deficits BM Roberts, CL Shaffer, PA Seymour, CJ Schmidt, GV Williams, ... Neuroreport 21 (5), 390-394, 2010 | 61 | 2010 |
| Discovery and Preclinical Characterization of 1-Methyl-3-(4-methylpyridin-3-yl)-6-(pyridin-2-ylmethoxy)-1H-pyrazolo-[3,4-b]pyrazine (PF470): A Highly Potent … L Zhang, G Balan, G Barreiro, BP Boscoe, LK Chenard, J Cianfrogna, ... Journal of medicinal chemistry 57 (3), 861-877, 2014 | 58 | 2014 |
| A rational chemical intervention strategy to circumvent bioactivation liabilities associated with a nonpeptidyl thrombopoietin receptor agonist containing a 2-amino-4 … AS Kalgutkar, J Driscoll, SX Zhao, GS Walker, RM Shepard, JR Soglia, ... Chemical research in toxicology 20 (12), 1954-1965, 2007 | 56 | 2007 |
| Enhancing ketamine translational pharmacology via receptor occupancy normalization CL Shaffer, SM Osgood, DL Smith, JH Liu, PE Trapa Neuropharmacology 86, 174-180, 2014 | 55 | 2014 |
| Strategies to optimize the brain availability of central nervous system drug candidates TT Wager, A Villalobos, PR Verhoest, X Hou, CL Shaffer Expert Opinion on Drug Discovery 6 (4), 371-381, 2011 | 55 | 2011 |
| Defining neuropharmacokinetic parameters in CNS drug discovery to determine cross-species pharmacologic exposure–response relationships CL Shaffer Annual Reports in Medicinal Chemistry 45, 55-70, 2010 | 53 | 2010 |
| Prevention of ketamine-induced working memory impairments by AMPA potentiators in a nonhuman primate model of cognitive dysfunction BM Roberts, DE Holden, CL Shaffer, PA Seymour, FS Menniti, CJ Schmidt, ... Behavioural brain research 212 (1), 41-48, 2010 | 49 | 2010 |
| Attenuation of ketamine-induced impairment in verbal learning and memory in healthy volunteers by the AMPA receptor potentiator PF-04958242 M Ranganathan, N DeMartinis, B Huguenel, F Gaudreault, MM Bednar, ... Molecular psychiatry 22 (11), 1633-1640, 2017 | 43 | 2017 |
| Positive allosteric modulation of AMPA receptors from efficacy to toxicity: the interspecies exposure-response continuum of the novel potentiator PF-4778574 CL Shaffer, RS Hurst, RJ Scialis, SM Osgood, DK Bryce, WE Hoffmann, ... Journal of Pharmacology and Experimental Therapeutics 347 (1), 212-224, 2013 | 43 | 2013 |
| An evaluation of using rat-derived single-dose neuropharmacokinetic parameters to project accurately large animal unbound brain drug concentrations AC Doran, SM Osgood, JY Mancuso, CL Shaffer Drug metabolism and disposition 40 (11), 2162-2173, 2012 | 43 | 2012 |
| Enzymatic N-Dealkylation of an N-Cyclopropylamine: An Unusual Fate for the Cyclopropyl Group CL Shaffer, MD Morton, RP Hanzlik Journal of the American Chemical Society 123 (2), 349-350, 2001 | 43 | 2001 |
| Unbound Brain-to-Plasma Partition Coefficient, Kp,uu,brain—a Game Changing Parameter for CNS Drug Discovery and Development I Loryan, A Reichel, B Feng, C Bundgaard, C Shaffer, C Kalvass, ... Pharmaceutical research 39 (7), 1321-1341, 2022 | 40 | 2022 |
